Randall Davis, MDRank:
Hematology & Oncology
Campus Address: SHEL 402
1720 2nd Avenue South, SHEL 402
Birmingham, AL 35294-3300
Phone: (205) 934-2992
For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.
Secondary: Biochemistry & Molecular Genetics
A graduate of Boston University in Boston, Massachusetts, Dr. Davis completed medical school at the University of Alabama School of Medicine (UASOM), where he also served his internship, residency, and the ABIM academic subspecialty research fellowship clinical investigator pathway in Hematology/Oncology. He is Associate Professor of Medicine, Microbiology, and Biochemistry and Molecular Genetics in the division of Hematology/Oncology. He is board certified in Internal Medicine and Hematology. His clinical interests center on lymphoproliferative disorders and B-CLL in particular.
My clinical interests include chronic disorders of lymphocytes particularly B cell chronic lymphocytic leukemia (CLL) and other lymphoproliferatve disorders.
Lymphocyte development and immunoreceptor biology. Dr. Davis' laboratory investigates lymphocyte development in normal and perturbed conditions to better understand the function of these cells in human immunity and disease. Current studies are focused on an extended family of Ig-like superfamily genes in humans and mice termed Fc receptor-like molecules (FCRL). FCRL family members are cell surface molecules with tyrosine-based activation (ITAM) or inhibitory (ITIM) motifs in their cytoplasmic tails that have preferential B lymphocyte expression, but are differentially expressed by B lineage malignancies and autoimmune disorders. Ongoing investigation in our laboratory indicates that these receptors function to modulate lymphocyte signaling and differentiation. Recent work characterizing a sixth member of this family (FCRL6), has identified its expression outside the B lineage distinctly on cytotoxic T and NK cells. These findings suggest that FCRL molecules may also influence effector lymphocyte function in cell mediated immunity. The recognition and characterization of this receptor family has significant implications for understanding connections between innate and adaptive immunity, the regulation and terminal differentiation of lymphocytes, and the pathogenesis of lymphoid malignancies and autoimmunity.
•Allendorf DJ, Davis RS. Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. JAMA. 2011 Jan 5;305(1):95-7.
•Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, Zhao M, Davis RS, Taranin AV, Najakshin AM, Hendershot LM, Burrows PD. FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. Int Immunol. 2011 Jan;23(1):43-53.
•Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD. FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol. 2010 Dec 15;185(12):7405-12
•Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol. 2010 Jul 1;185(1):23-7.
•Campbell JA, Davis RS, Lilly LM, Fremont DH, French AR, Carayannopoulos LN. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J Immunol. 2010 Jul 1;185(1):28-32.
•Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, Wiener H, Tiwari H, Kimberly RP, Davis RS. The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells. (2009) Arthritis Rheum. 60:3510-2.
•Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.(2009) Cancer Cell 16(2):161-71.
•Schreeder DM, Pan J, Li FJ, Vivier E, Davis RS: FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. (2008) Eur. J. Immunol. 38:3159-66.
•Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS: FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.(2008) Blood. 112:179-87.
•Davis RS. Fc Receptor-Like Molecules. Annu Rev Immunol. (2007) 25:525-60.
•Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, and Davis RS. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol. 2006 Nov 15;177(10):6815-23.
•Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R, Burrows PD, Cooper MD, Davis RS. New nomenclature for Fc receptor-like molecules. Nat Immunol. 2006 May;7(5):431-2.
•Masuda K, Davis RS, Maruyama T, Zhang J, He T, Cooper MD, O-Wang J, Burrows PD. FcRY, an Fc receptor related gene differentially expressed during B lymphocyte development and activation. Gene. 2005 Dec 19;363:32-40.
•Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, Cooper MD. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med. 2005 Sep 19;202(6):783-91. Epub 2005 Sep 12.
•Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD. An extended family of Fc receptor relatives. Eur J Immunol. 2005 Feb 2;35(3):674-680.
•Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD.FcRH1: an activation coreceptor on human B cells. Blood. 2005 Feb 1;105(3):1121-6. Epub 2004 Oct 12.
•Davis RS, Stephan RP, Chen CC, Dennis G Jr, Cooper MD. Differential B cell expression of mouse Fc receptor homologs. Int Immunol. 2004 Sep;16(9):1343-53. Epub 2004 Aug 09.
•Ehrhardt, G. R. A., Davis, R. S., Hsu, J. T., Leu, C-M., Ehrhardt, A., and Cooper, M. D. The inhibitory potential of Fc receptor homolog 4 on memory B cells. (2003) Proc. Natl. Acad. Sci. USA., 100:13489-13494.
•Davis, R. S., Dennis, G., Odom, M. R., Gibson, A. W., Kimberly, R. P., Burrows, P. D., and M. D. Cooper: Fc Receptor Homologs: Newest Members of a Remarkably Diverse Fc Receptor Gene Family. (2002) Immunol. Rev. 190:123-136.
•Davis, R. S., Li, H., Chen, C.-C., Wang, Y.-H., Cooper, M. D., and Burrows, P. D. Definition of an Fc receptor Related Gene (FcRX) Expressed in Human and Mouse B Cells. (2002) Int. Immunol. 14:1075-1083.
•Davis, R. S., Dennis, G., Kubagawa, H., and M. D. Cooper: Fc Receptor Homologs (FcRH1-5) Extend the Fc Receptor Family. (2002) Curr.Top Microbiol. Immunol., 266: 85-112.
•Davis, R. S., Wang, Y., Kubagawa, H., and M. D. Cooper: Identification of a Family of Fc Receptor Homologs with Preferential B Cell Expression. (2001) Proc. Natl Acad. Sci., 98: 9772-9777.
Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.
Postdoc Positions Available
A postdoctoral position is available in the laboratory of Dr. Randall Davis to investigate pathways of lymphocyte development and function of a novel family of Fc receptor-like molecules (FCRL). Studies involve establishing human and mouse disease models, exploring signaling potential and gene regulation. M.D. and/or Ph.D. is required. Please send curriculum vitae and names of three references to: Randall S. Davis, M.D. 1825 University Blvd SHEL 401, Birmingham, AL 35294-3300.
We have a very interactive group comprised of graduate students, medical residents, postdoctoral fellows, and research associates.